FREMONT, Calif., April 15 /PRNewswire-FirstCall/ -- Abgenix, Inc.
(Nasdaq: ABGX) today announced upcoming presentations of clinical and
preclinical data from studies of panitumumab, a fully human monoclonal
antibody currently in pivotal clinical trials as a third line monotherapy in
colorectal cancer, will be presented at the American Association for Cancer
Research (AACR) annual meeting April 16-20 in Anaheim, California and the 41st
American Society of Clinical Oncology (ASCO) annual meeting May 13-17 in
Orlando, Florida.
AACR
The following abstracts are being presented at the AACR meeting:
-- "Gene Expression Profiles Can Predict Panitumumab Monotherapy
Responsiveness in Xenograft Models -- A 'Balanced' Approach" will be
presented in the Cellular and Molecular Biology 1, Expression Profiling
and Analysis of Cancer Biology session on Sunday, April 17 from
8:00 a.m. to 12:00 p.m. (Abstract #1);
-- "Activity of Panitumumab Against Mutant and Wild Type EGFr NSCLC Cell
Lines and Xenografts" will be presented in the Molecular Biology 56
session on Tuesday, April 19 from 1:00 PM to 5:00 PM (Abstract #4494);
and
-- "Identification and Preclinical Characterization of EGFr Somatic Gene
Mutations from a Panitumumab Phase 2 NSCLC Clinical Trial: Discovery of
a Novel Mutation with Panitumumab Sensitivity and Gefitinib Resistance"
will be presented in the Late-Breaking Poster session Tuesday, April 19
from 1:00 p.m. to 5:00 p.m. (Abstract #LB205).
ASCO
The following abstracts will be presented at ASCO in May:
-- "Updated Results from a Dose and Schedule Study of Panitumumab
(ABX-EGF) Monotherapy, in Patients with Advanced Solid Malignancies"
will be presented on Sunday, May 15 from 8:00 a.m. to 12:00 p.m. during
the General Poster Session; and
-- "Safety and Efficacy of Panitumumab Monotherapy in Patients with
Metastatic Colorectal Cancer (mCRC)" will be presented during a Poster
Discussion on Tuesday May 17 from 8:00 a.m. to 12:00 p.m.
About Panitumumab
Co-developed by Amgen and Abgenix, panitumumab is an investigational
product in a novel class of targeted cancer treatments called epidermal growth
factor receptor (EGFr) inhibitors. Panitumumab (formerly ABX-EGF) is the first
fully human monoclonal antibody directed against EGFr and is being evaluated
as both a monotherapy and in combination with other agents for the treatment
of various types of cancer, including colorectal, lung and kidney. Panitumumab
is generated with Abgenix's XenoMouse(R) technology, which creates a fully
human monoclonal antibody that contains no murine (mouse) protein. The fully
human nature of panitumumab may result in a favorable safety profile with a
low incidence of infusion reactions, antigenicity and allergic response. These
are attributes currently being investigated in clinical trials. Pivotal
clinical studies evaluating panitumumab as a third-line monotherapy in
colorectal cancer patients are ongoing with a convenient every-other-week
dosing regimen.
About Abgenix
Abgenix is a biopharmaceutical company focused on the discovery,
development and manufacturing of human therapeutic antibodies. The company's
antibody development platform includes a leading technology and state-of-the-
art manufacturing capabilities that enable the rapid generation, selection and
production of high affinity, fully human antibody product candidates to a
variety of disease targets. Abgenix leverages its leadership position in human
antibody technology to build a diversified product portfolio through its own
development efforts and the establishment of collaborations with multiple
pharmaceutical and biotechnology companies. For more information on Abgenix,
visit the company's website at http://www.abgenix.com.
Certain statements in these materials, including information presented in
the letter to stockholders, are forward-looking statements with the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These include forward-looking statements about Abgenix's
technologies, product development activities, clinical trials and clinical
trial results, the potential submission of a biologic license application for
panitumumab, collaborative arrangements, process sciences and manufacturing
activities, projected financial and operating results, and achievement of
milestone or similar payments or other revenues. All such statements are
subject to a number of uncertainties that could cause actual results to differ
materially from the statements made, including risks associated with
conducting clinical trials, regulatory approval processes and meeting
requirements for regulatory approval, the progress of research and product
development programs, product manufacturing, competitive products and
services, capital requirements, the extent and breadth of Abgenix's patent
portfolio, and other factors set forth in Abgenix's public filings with the
Securities and Exchange Commission. The forward-looking statements included in
these materials are made only as of the date of publication and Abgenix does
not undertake any obligation to update any forward-looking statements.
SOURCE Abgenix, Inc.
 back to top
Related links:
http://www.abgenix.com
CONTACT:
Ami Knoefler, Senior Director, Corporate
Communications and Investor Relations, of Abgenix, Inc.,
+1-510-284-6350, or +1-510-284-6605
|
